What are the top longevity startups by revenue today?

The ranking of top startups in the longevity market by revenue

Below is a table ranking all the companies in this market by their current revenue scale. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Longevity Market.

What are the top longevity startups by revenue today?

Biote currently has the strongest clean revenue figure in the longevity market at $192.2 million for 2025, while Niagen Bioscience follows at $129.4 million and several private companies now sit around the $100 million mark.

The private-company ranking gets less clean very quickly. Hone Health reached an estimated $113.5 million ARR in 2025, Function Health reached an estimated $100 million revenue run-rate, and AgelessRx says it generates more than $70 million annually. Life Extension could be bigger than several of them, but the current $100 million to $500 million estimate is far too wide to give it a precise position.

The top of the market already contains several nine-figure businesses, but only Biote and Niagen give us recent, filed company-wide revenue that can be compared without much interpretation.

Rank	Company	Best current evidence	Metric	Evidence quality
1	Biote	$192.2M	FY2025 revenue	Filed
2	Niagen Bioscience	$129.4M	FY2025 net sales	Filed
3	Hone Health	$113.5M	2025 ARR	Specialist estimate
4	Life Extension	$100M–$500M	Annual revenue estimate	Third-party estimate
5	Function Health	$100M	Revenue run-rate	Specialist estimate
6	AgelessRx	>$70M	Annual revenue	Founder disclosed
7	L-Nutra	~$50M	Annual revenue estimate	Third-party estimate
8	OneSkin	$40M–$50M	FY2025 revenue estimate	Third-party estimate
9	Fountain Life	$25M–$50M	Annual revenue estimate	Third-party estimate
10	Human Longevity	$25M–$50M	Annual revenue estimate	Third-party estimate

What should actually count as a longevity company in this ranking?

For this longevity revenue ranking, we include companies whose core business is clearly tied to healthy aging, biological-age measurement, preventive health, hormone optimization, longevity-focused nutrition or interventions designed to extend healthspan.

That definition is broader than longevity biotech. Biote sells hormone optimization and explicitly describes its business around healthy aging. Niagen Bioscience sells NAD+ products aimed at healthier aging. Function Health and Neko Health focus on finding health risks earlier. Hone Health and AgelessRx combine diagnostics with treatments commonly marketed around longevity and metabolic health.

A narrower “venture-backed startup only” definition changes the leaderboard. Biote and Niagen are public companies, while Life Extension has been around for decades. If we exclude those older businesses, Hone Health, Function Health and AgelessRx become the clearest large private longevity companies.

We prefer showing that distinction rather than pretending everyone means exactly the same thing when they search for “longevity startups.”

Is Biote really the biggest longevity company by revenue?

Biote currently has the strongest case for the number-one spot because its $192.2 million revenue figure comes directly from filed 2025 financial statements.

Biote reported $186.9 million of product revenue and $5.3 million of service revenue. Few companies in this market give us a number with that level of clarity.

The more recent results are less impressive. Biote's 2025 revenue fell 2.5% from $197.2 million the year before. During the first half of 2026, revenue fell another 8.9% year over year to $89.2 million. Second-quarter revenue was $44.2 million, down 9.5%.

The company has linked part of the weakness to lower hormone-pellet procedure volumes, a sales reorganization and disruption around a voluntary product recall. Dietary-supplement revenue has held up better.

Biote still leads this ranking on hard revenue, although the latest operating trend is clearly weaker than the headline $192 million figure might suggest.

Could Life Extension actually make more revenue than Biote?

Life Extension could be larger than Biote, but the public revenue evidence is currently too imprecise for us to put it first.

One current company-data estimate puts Life Extension somewhere between $100 million and $500 million of annual revenue. Other estimates fall within that range. That already tells us Life Extension is a substantial business, but it does little to settle the ranking.

At $120 million, Life Extension would sit below Niagen. At $250 million, it would lead the table. A $400 million figure would change the picture again.

The sensible treatment is to keep Life Extension near the top while marking its position as uncertain. Choosing the midpoint would look neat, but the source itself does not support that precision.

Is Niagen Bioscience bigger than Hone Health today?

Niagen Bioscience still has stronger evidence of greater revenue scale than Hone Health because Niagen reported $129.4 million of actual 2025 net sales.

Niagen grew 30% that year, with Tru Niagen consumer products and Niagen ingredient sales driving the business. It also reported $17.4 million of net income, which makes it one of the rare sizeable and profitable companies in this ranking.

Hone Health reached an estimated $113.5 million ARR during 2025. That puts the two companies surprisingly close in commercial scale, but ARR and recognized annual sales are different measurements.

The latest Niagen numbers also make the comparison more interesting. First-half 2026 sales were $61.3 million versus $61.6 million a year earlier, and second-quarter sales slipped to $29.8 million. The company is still large, but its growth has cooled after the strong 2025 jump.

Hone therefore looks much closer to Niagen than it did a couple of years ago, even if Niagen remains ahead on the cleaner number.

How much revenue does Hone Health make?

Hone Health is now roughly a $100 million-plus longevity business, with specialist research estimating $113.5 million ARR in 2025.

That estimate was up from $69.7 million at the end of 2024, an increase of roughly 82%. Hone's monthly growth also accelerated during the year.

The company has moved well beyond its original testosterone-replacement niche. It now sells women's hormone care, GLP-1 weight-loss treatments and longevity-related interventions such as metformin and glutathione alongside blood testing and physician follow-up.

That expansion helps explain the revenue figure: Hone is becoming a broader health-optimization platform rather than a single-treatment telehealth company.

We still rank the $113.5 million below filed revenue of a similar size because it is estimated ARR. Even with that caveat, Hone is already one of the largest private longevity businesses we found.

How big is Function Health now?

Function Health has already reached roughly nine-figure commercial scale, with specialist research estimating a $100 million revenue run-rate.

The company grew unusually quickly after launching in 2023. Function had around 40,000 members in mid-2024 and passed 200,000 by the following year according to the data available when the $100 million estimate was produced.

The model is easy to understand. Members pay for large recurring biomarker panels and health interpretation, while Function relies heavily on external laboratory infrastructure rather than building clinics everywhere itself.

Function has since broadened the product. The company acquired Ezra and added MRI and CT imaging, then raised a $298 million Series B at a $2.5 billion valuation. Function says it is now trusted by hundreds of thousands of members.

The $100 million figure remains an estimated run-rate rather than filed annual revenue, but Function has clearly moved into the top tier of private longevity businesses.

Has AgelessRx quietly become one of the biggest longevity startups?

AgelessRx has quietly become one of the largest longevity-focused private companies, with founder Anar Isman discussing annual revenue above $70 million.

The figure came from a long-form founder interview focused on how AgelessRx grew from a side project into a sizeable telehealth business. The company subsequently amplified the interview publicly.

AgelessRx sells access to treatments such as metformin, low-dose naltrexone and hormone therapies, giving the business recurring treatment revenue rather than relying only on one-off tests.

The capital efficiency is particularly unusual. The founder interview described a company doing more than $70 million of revenue after raising only around $6 million to $7 million.

That puts AgelessRx well ahead of many longevity startups that have raised considerably more money but still do not publish meaningful revenue figures.

Which longevity companies already make more than $50 million a year?

At least six longevity companies have reasonably strong evidence of commercial scale around or above $50 million, with L-Nutra sitting close to the boundary.

Biote and Niagen clear the threshold comfortably on filed annual revenue. Hone and Function clear it on estimated ARR or revenue run-rate. Life Extension almost certainly exceeds $50 million even though its current range is frustratingly broad, and AgelessRx says it makes more than $70 million.

L-Nutra sits around $50 million on current outside estimates. The company has also reported more than $250 million in cumulative revenue from its broader commercial history, which confirms substantial scale without telling us exactly what one current year looks like.

OneSkin comes next at an estimated $40 million to $50 million.

Company	Best scale evidence	Clearly above $50M?
Biote	$192.2M FY2025 revenue	Yes
Niagen Bioscience	$129.4M FY2025 net sales	Yes
Hone Health	$113.5M ARR estimate	Yes
Life Extension	$100M–$500M estimate	Yes
Function Health	$100M revenue run-rate estimate	Yes
AgelessRx	>$70M founder disclosure	Yes
L-Nutra	~$50M annual estimate	Around threshold
OneSkin	$40M–$50M FY2025 estimate	Not clearly

Which longevity supplement companies make the most revenue?

Niagen Bioscience and Life Extension appear to be the largest longevity supplement businesses by current revenue scale, while L-Nutra sits in a smaller but still meaningful tier.

Niagen gives us the best numbers. The company recorded $129.4 million in 2025 net sales, including $97.7 million from Tru Niagen products and another $27.9 million from ingredients.

Life Extension could be larger, but its available revenue estimates are too wide to prove it.

L-Nutra has built a substantial business around ProLon and fasting-mimicking nutrition. Its cumulative revenue has passed $250 million according to company disclosures, while current annual estimates put the business closer to $50 million.

Elysium Health, Timeline and NOVOS appear considerably smaller on the public numbers we found.

Supplements may get less attention than AI diagnostics or full-body scanning these days, but they still generate some of the largest actual revenue pools in longevity.

Is OneSkin already a major longevity company?

OneSkin has become a serious consumer longevity business, with 2025 revenue estimated between $40 million and $50 million.

That puts OneSkin below the nine-figure leaders but ahead of most of the longevity brands in our research.

OneSkin's positioning is also unusual. Instead of selling blood tests, supplements or clinical care, the company monetizes longevity through skincare built around OS-01, a peptide developed around skin aging and cellular senescence.

The company raised another $20 million in 2025, taking reported funding above $40 million.

We would still avoid treating the $40 million to $50 million range like audited revenue. It comes from third-party financial research. But even the lower end makes OneSkin one of the larger consumer longevity companies currently operating.

Are longevity clinics actually making serious revenue?

Longevity clinics now produce tens of millions of dollars in revenue, although physical clinic businesses still appear smaller than the leading telehealth, supplement and diagnostics platforms.

Fountain Life and Human Longevity are each estimated around $25 million to $50 million annually. Both sell high-priced preventive programs built around imaging, advanced diagnostics and physician-led care.

Lanserhof gives us a more concrete financial datapoint. Public financial information for Lanserhof GmbH shows €21.8 million in 2025 revenue. That figure should be read carefully because it covers a specific corporate entity rather than necessarily every Lanserhof property worldwide.

Smaller clinic businesses then drop toward the single-digit or low-double-digit millions. Longevium reports around $10 million, while Anderson Longevity Clinic has published location-level revenue around $3.9 million for its strongest disclosed clinic.

Clinic economics can be attractive, but adding each new location requires physical capacity, staff and medical operations. The fastest-growing membership companies do not carry the same expansion burden.

How much revenue does Neko Health make?

Neko Health has become a very large preventive-health company operationally, but we still do not have a dependable company-disclosed revenue figure.

The outside estimates we found put Neko in roughly the low tens of millions for 2025, with one estimate around $21.9 million. We would not treat that figure as comparable in quality with filed Biote or Niagen revenue.

What we can measure much more confidently is Neko's operating scale. The company says its latest health dataset covers more than 80,000 members in Sweden and the UK, while more recent reporting around its U.S. expansion puts total customers above 100,000.

Neko has also become vastly better funded. After an earlier $260 million raise at a $1.7 billion valuation, the company raised another $700 million in 2026 at a valuation approaching $7 billion. Its first New York location is opening with more than 25,000 people already on the local waitlist.

The contrast with Function is useful. Function reached large membership and revenue scale using an asset-light laboratory network. Neko owns much more of the customer experience through dedicated scanning centers and proprietary hardware, which makes expansion more capital intensive.

Neko is currently much bigger than its weak public revenue disclosure makes it look, but we will not manufacture a revenue number from customer counts or scan prices.

Which preventive-health startups are already above $20 million in revenue?

Function Health is clearly the largest preventive-health startup in this group on available revenue evidence, followed by several companies that appear to sit in the $20 million to $50 million range.

Function reached an estimated $100 million revenue run-rate. Fountain Life and Human Longevity are both estimated at $25 million to $50 million.

Neko Health has an outside estimate around $21.9 million, although the company's operating scale now suggests that figure should be treated cautiously rather than as a precise current number. Lanserhof GmbH reported €21.8 million.

InsideTracker is harder to place because current estimates span roughly $10 million to $50 million. TruDiagnostic, Viome, SiPhox Health and Mito Health appear below the $20 million level on the usable financial evidence we found.

Company	Current financial evidence	Main business
Function Health	$100M run-rate estimate	Biomarker membership
Fountain Life	$25M–$50M estimate	Preventive clinics
Human Longevity	$25M–$50M estimate	Precision-health clinics
Neko Health	~$21.9M outside estimate	Preventive body scanning
Lanserhof GmbH	€21.8M reported revenue	Longevity clinics
InsideTracker	$10M–$50M estimate	Biomarker testing
TruDiagnostic	$9.8M estimate	Epigenetic testing
Viome	$7.2M observed e-commerce GMV	Molecular testing

Why are some longevity startups worth billions before they make much revenue?

Longevity investors are paying heavily for future platform potential, so valuations can run far ahead of the revenue we can verify today.

Neko Health is the clearest example. Its valuation has climbed toward $7 billion after a $700 million financing round even though the company does not publish consolidated annual revenue. Investors are backing the possibility of a global preventive-health network built around proprietary scanners, software and longitudinal health data.

Function Health reached a $2.5 billion valuation after building much stronger visible commercial scale, including hundreds of thousands of members and an estimated $100 million revenue run-rate.

The opposite example is AgelessRx. The founder says the company generates more than $70 million annually after raising only around $6 million to $7 million.

Those three companies show why funding is a poor shortcut for revenue. A telehealth company can start collecting money almost immediately. A clinic-and-hardware network needs much more capital. A therapeutic biotech can burn large amounts of cash for years before selling anything.

Investors may ultimately be right about the bigger opportunity, but the funding leaderboard and revenue leaderboard currently look very different.

Which big longevity startups still do not disclose revenue?

Superpower, Prenuvo, Everlab and several other fast-growing longevity companies still lack public revenue disclosures strong enough for us to rank them numerically.

Superpower now sells a preventive-health membership built around more than 150 biomarkers, personalized guidance and an on-demand care team. The company raised a $30 million Series A and says it has already processed more than six million biomarkers, but we found no solid company-wide revenue disclosure.

Prenuvo passed 100,000 completed scans in late 2024 and has continued expanding its whole-body MRI network. Multiplying scans by today's retail price would be tempting and wrong because pricing, timing, packages and historical prices vary.

Everlab is another increasingly important example. The company now says it supports more than 18,000 members, has completed more than 40,000 consultations and grew 23-fold during 2025, yet it still does not give an absolute revenue number.

Other companies such as Lucis, NiaHealth and GlycanAge publish users, tests or people served rather than revenue.

These businesses belong in the market analysis. They simply should not receive invented revenue positions.

Is Superpower already as big as Function Health?

Superpower has reached meaningful scale, but Function Health still has much stronger evidence of a larger business today.

Function has hundreds of thousands of members and an estimated $100 million revenue run-rate. Superpower has disclosed strong adoption signals, six million-plus biomarkers processed and a rapidly expanding membership product, but no comparable revenue figure.

The companies also price and package preventive care differently, so comparing raw customer counts would still leave us guessing about revenue per member.

Superpower's $30 million Series A and nationwide lab network show that it has moved beyond an early experiment. Function is simply further ahead on the financial evidence available today.

Are the fastest-growing longevity startups already the biggest?

Some of the fastest-growing longevity startups are catching the older leaders quickly, but absolute revenue and recent growth still tell different stories.

Function's estimated run-rate increased several hundred percent during its rapid expansion phase. Hone's estimated ARR grew about 82% during 2025.

Biote moved in the opposite direction. Its 2025 revenue fell 2.5%, followed by another 8.9% year-over-year decline in the first half of 2026.

Niagen grew 30% in 2025, although sales were roughly flat year over year in the first half of 2026.

Biote and Niagen still hold the cleaner large revenue numbers while Function and Hone have shown much faster recent expansion. Function and Hone are now big enough that the gap matters less than it did a few years ago.

What happened to InsideTracker, Elysium Health and Viome?

InsideTracker, Elysium Health and Viome remain recognizable longevity brands, but current public financial evidence puts them well below the market leaders.

InsideTracker is particularly hard to rank because outside estimates currently span roughly $10 million to $50 million. Even the upper end remains below Function, Hone or Niagen.

Elysium Health is commonly estimated in the $10 million to $25 million annual range. The brand remains important in NAD+ supplements, but Niagen Bioscience now operates at a much larger reported sales scale.

For Viome, one of the better recent commercial measurements we found is around $7.2 million of observed e-commerce GMV. That is website transaction volume, not consolidated company revenue, so we keep it labeled as such.

These companies helped shape the first wave of consumer longevity, but newer platforms have grown much faster commercially.

Which longevity business models make the most money today?

Hormone optimization, supplements, recurring diagnostics and telehealth currently generate the largest proven revenue in longevity.

Biote built a $192.2 million business around hormone optimization and related products. Niagen generated $129.4 million from consumer NAD+ products and ingredients. Hone and AgelessRx combine testing with recurring treatment, while Function built its scale around repeated biomarker testing.

Consumer products can also get large. OneSkin is already estimated at $40 million to $50 million, and Life Extension may sit well above $100 million.

Physical clinics can reach tens of millions, but we have yet to find a clean clinic operator approaching the top revenue tier.

The commercial pattern is practical: companies are making the most money where customers can buy something repeatedly right now.

Are longevity biotech startups making meaningful revenue yet?

Most pure longevity biotech startups still generate little product revenue because they are developing therapies that have not reached the market.

Companies working on cellular reprogramming, senolytics, gene therapies or other direct biological interventions often spend years in research and clinical development before they can sell an approved treatment.

That creates a large gap between scientific ambition and commercial revenue.

The biggest businesses in this ranking generally sell services or products that already fit into existing consumer behavior: blood tests, hormones, supplements, skincare, scans and medical memberships.

A revenue ranking consequently tells us much more about what people are paying for now than about which aging technology could eventually have the greatest medical impact.

How concentrated is longevity company revenue?

Longevity revenue is heavily concentrated among a small group of companies, followed by a sharp drop into a fragmented middle market.

Only a handful have evidence around or above $100 million: Biote, Niagen, Hone, Function and probably Life Extension. AgelessRx forms another sizeable step at more than $70 million.

OneSkin, Fountain Life, Human Longevity and several clinic or diagnostics companies then cluster roughly between $20 million and $50 million.

Below them sits a long tail of companies under $20 million, plus another group whose revenue cannot be measured at all from public information.

The market has clearly created real businesses, but it still lacks a deep bench of companies generating $50 million to $100 million annually.

Are longevity startups finally becoming real businesses?

Longevity has already produced several substantial businesses, so the commercial market is no longer something we need to infer from funding rounds or scientific enthusiasm.

We found two companies above $100 million on recent filed revenue, two private companies around $100 million on specialist ARR or run-rate estimates, another private business above $70 million from a founder disclosure, and several companies in the $20 million to $50 million range.

The revenue also comes from different customer behaviors. People are paying for hormone optimization, NAD+ supplements, recurring blood panels, preventive scans, skincare, nutrition programs and physician-led memberships.

That breadth is encouraging because longevity spending is not resting on one fashionable product.

What remains much less proven is whether today's leaders can keep compounding until several become billion-dollar-revenue healthcare businesses.

So who are the top longevity startups by revenue today?

Biote currently leads the broad longevity ranking with $192.2 million of 2025 revenue, followed by Niagen Bioscience at $129.4 million, while Hone Health and Function Health have both reached roughly nine-figure private-company scale.

Hone is estimated at $113.5 million ARR, Function at a $100 million revenue run-rate, and AgelessRx says annual revenue exceeds $70 million. Life Extension may belong even higher in the list, but the available $100 million to $500 million estimate is too wide for a confident position.

If we use the narrower meaning of “startup” and remove older public or long-established companies, Hone Health, Function Health and AgelessRx become the clearest private revenue leaders. OneSkin then forms part of the next group at an estimated $40 million to $50 million.

The category's most ambitious anti-aging biotechnology companies barely appear in this leaderboard. For now, longevity makes most of its money through products and services people can already buy: hormones, diagnostics, telehealth, supplements and preventive care.

[PLACEHOLDER ENCART]